Comparison of Vortioxetine and Desvenlafaxine in Adult Patients Suffering From Depression
VIVRE
A Randomised, Double-blind, Parallel-group, Active Controlled Study Evaluating the Efficacy of Vortioxetine Versus Desvenlafaxine in Adult Patients Suffering From Major Depressive Disorder With Partial Response to SSRI Treatment
1 other identifier
interventional
605
11 countries
79
Brief Summary
The purpose of this study is to compare the efficacy of vortioxetine versus desvenlafaxine after 8 weeks of treatment in patients that have tried one available treatment without getting the full benefit
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_4 major-depressive-disorder
Started Jun 2020
Shorter than P25 for phase_4 major-depressive-disorder
79 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 18, 2020
CompletedFirst Submitted
Initial submission to the registry
June 23, 2020
CompletedFirst Posted
Study publicly available on registry
June 25, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 6, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
February 4, 2022
CompletedFebruary 14, 2022
February 1, 2022
1.6 years
June 23, 2020
February 11, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Change in Montgomery and Åsberg Depression Rating Scale (MADRS) total score
The Montgomery and Åsberg Depression Rating Scale (MADRS) is a 10-item rating scale designed to assess the severity of the symptoms in depressive illness and to be sensitive to treatment effects. Symptoms are rated on a 7-point scale from 0 (no symptom) to 6 (severe symptom). The total score of the 10 items ranges from 0 to 60, with higher values indicating worse outcome.
From baseline to Week 8
Secondary Outcomes (15)
Remission (defined as a MADRS total score =<10)
At Week 8
Response (defined as a => 50% decrease from baseline in MADRS total score)
At Week 8
Change in MADRS anhedonia factor score
From baseline to Week 8
Change in Digital Symbol Substitution Test (DSST) total score
From baseline to Week 8
The proportion number of Hard Choice/number of High Reward trials and number of Low choice/number of Low Reward trials when performing the Effort- Expenditure for Rewards Task (EEfRT)
From baseline to Week 8
- +10 more secondary outcomes
Study Arms (2)
Vortioxetine
EXPERIMENTAL8 weeks treatment
Desvenlafaxine
ACTIVE COMPARATOR8 weeks treatment
Interventions
Eligibility Criteria
You may qualify if:
- The patient has a primary diagnosis of single or recurrent MDD, diagnosed according to DSM-5®. The current MDE must be confirmed using the Mini International Neuropsychiatric Interview (MINI).
- The patient has a MADRS total score ≥24 at screening and baseline.
- The patient has had the current MDE for ≥3 months and \< 12 months.
- The patient has been treated with an SSRI as monotherapy (citalopram, escitalopram, paroxetine, sertraline) for at least 6 weeks at licensed dose for the current MDE with a partial response and is a candidate for a switch in the investigator's opinion.
- The patient wants to switch antidepressant treatment.
You may not qualify if:
- The patient has any other disorder for which the treatment takes priority over treatment of MDD or is likely to interfere with study treatment or impair treatment compliance.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- H. Lundbeck A/Slead
Study Sites (80)
Clinica Privada Banfield
Banfield, Buenos Aires, B1828CKR, Argentina
Cenydet-Centro Neurobiologico Y De Estres Traumatico-Biopsychomedical Research Group Srl
Ciudad Autonoma de Buenos Aires, Buenos Aires, C1058AAJ, Argentina
Fundacion para el Estudio y Tratamiento de las enfermedades mentales FETEM
Ciudad Autonoma de Buenos Aires, Buenos Aires, C1133AAH, Argentina
INAPsi (Instituto Nacional de Psicopatologia)
Ciudad Autonoma de Buenos Aires, Buenos Aires, C1405BOA, Argentina
Clinica Privada De Salud Mental Santa Teresa De Avila
La Plata, Buenos Aires, 1900, Argentina
Instituto De Neurociencias San Agustin SA
La Plata, Buenos Aires, B1900BHE, Argentina
Sanatorio Prof. Leon S. Morra S.A.
Córdoba, Providencia de Cordo, X5009BIN, Argentina
CIAP (Centro de Investigacion y Asistencia en Psiquiatria)
Rosario, Santa Fe Province, 2000, Argentina
CINME (Centro de Investigaciones Metabolicas de Buenos Aires)
Buenos Aires, C1056ABJ, Argentina
CEN (Centro Especializado Neurociencias)
Córdoba, 5000, Argentina
Instituto Modelo de Neurologia Fundacion Lennox
Córdoba, X5000FAL, Argentina
Instituto Medico DAMIC - Fundacion Rusculleda
Córdoba, X5003DCE, Argentina
Centro De Asistencia E Investigacion En Neurociencias CENAIN
Mendoza, 5500, Argentina
Resolution Psicopharmacology Research Institute
Mendoza, M5500BCR, Argentina
Algemeen Ziekenhuis St. Lucas-St. Jozef
Bruges, 8310, Belgium
SINAPS - University Antwerpe- Psychiatrisch Ziekenhuis Duffel
Duffel, 2570, Belgium
Cliniques De Mont-Godinne
Yvoir, 5530, Belgium
MHAT Dr. Hristo Stambolski
Kazanlak, 6100, Bulgaria
UMHAT Sv. Ivan Rilski EAD
Plovdiv, 4002, Bulgaria
Center For Mental Health-Rousse
Rousse, 7003, Bulgaria
MC Complete Medical Solutions
Samokov, 2000, Bulgaria
Centre for Mental Health- Sofia
Sofia, 1202, Bulgaria
Diagnostic Consultative Center Mladost-M Varna OOD
Varna, 9020, Bulgaria
Clintrial s.r.o.
Prague, Prague 10, 100 00, Czechia
Dr.Jan Holan MD, Office of
Brno, 61500, Czechia
Meditrine s.r.o. - Psychiatricka Ambulance, Lecebne Centrum
Havířov, 73601, Czechia
Clinline services s.r.o.
Hostivice, 25301, Czechia
Neuropsychiatrie HK, s.r.o.
Hradec Králové, 50009, Czechia
National Institute of Mental Health
Klecany, 25067, Czechia
Psychiatricka Ambulance
Kutná Hora, 28401, Czechia
A-Shine s.r.o.
Pilsen, 31200, Czechia
Institut neuropsychiatricke pece
Prague, 18600, Czechia
Marienthali Kliinik
Tallinn, 11315, Estonia
Psihiatrijas Centrs
Liepāja, Liepajas Rajons, 3401, Latvia
Riga Centre Of Psychiatry And Addiction Disorders
Riga, 1005, Latvia
Sigulda Hospital Outpatient Clinic
Sigulda, LV-2150, Latvia
CRI Centro Regiomontano de Investigacion SC
Monterrey, Nuevo León, 64060, Mexico
Medical Care and Research S.A. de C.V.
Mérida, Yucatán, 97070, Mexico
Health Pharma Professional Research S.A. de C.V.
Mexico City, 03100, Mexico
Region Specialized Psychiatric Hospital No.2
Stavropol Region, Kochubeev District, 357034, Russia
Leningrad Regional Psychoneurological Dispensary
Roshchino, Leningradskaya Oblast', 188820, Russia
Arkhangelsk Regional Clinical Mental Hospital
Arkhangelsk, 163530, Russia
GUZ Engels Psychiatric Hospital
Engel's, 413124, Russia
Moscow Scientific Research Institute of Psychiatry
Moscow, 107076, Russia
Clinic named after professor Yu. N. Kasatkin FGBOU DPO RMANPO Minzdrava Rossii
Moscow, 125284, Russia
Nizhny Novgorod Region State Institution Of Healthcare Clinical Psychiatric Hospital 1 Of Nizhny ...
Nizhny Novgorod, 603155, Russia
Rostov State Medical University of the Minzdravsotsrazvitiya of Russia
Rostov-on-Don, 344022, Russia
LLC Medical Center Nova Vita
Rostov-on-Don, 344082, Russia
St. Nicolas State Psychiatric Hospital
Saint Petersburg, 190121, Russia
Hospital OrKli , LLC
Saint Petersburg, 199178, Russia
LLC Astarta
Saint Petersburg, 199226, Russia
Saratov State Medical University
Saratov, 410028, Russia
State Budgetery Educational Institution Of Higher Professional Education Smolensk State Medical U...
Smolensk, 214019, Russia
Yaroslavl Regional Clinical Psychiatry Hospital
Yaroslavl, 150003, Russia
Psychiatricka ambulancia, MENTUM, s.r.o.
Bratislava, 82007, Slovakia
Epamed, S.R.O
Košice, 040 01, Slovakia
Psycholine S.R.O.
Rimavská Sobota, 97901, Slovakia
Crystal Comfort, s.r.o.
Vranov Nad Topou, 09301, Slovakia
BONA MEDIC s.r.o.
Zlaté Moravce, 95301, Slovakia
Psychiatricka Ambulancia
Zlaté Moravce, 95301, Slovakia
Hospital Universitario Fundacion Alcorcon
Alcorcón, Madrid, 28922, Spain
Centro De Salud Mental La Corredoria
Oviedo, Principality of Asturias, 33011, Spain
Hospital De La Santa Creu I Sant Pau
Barcelona, 08041, Spain
Hospital Psiquiatric de Palma de Mallorca
Palma de Mallorca, 07011, Spain
Smaert & Psykiatricentrum Malmoe
Malmo, Skåne County, 21137, Sweden
Affecta Psyikiatri AB
Halmstad, 302 48, Sweden
ProbarE i Lund
Lund, 22222, Sweden
ONE LIFETIME Lakarmottagning
Skövde, 541 50, Sweden
ProbarE
Stockholm, 11329, Sweden
Communal Non-commercial Enterprise Cherkasy regional psychiatric hospital of Cherkasy regional co...
Smila, Cherkasy Oblast, 20708, Ukraine
Communal Non-Commercial Enterprise of Kharkiv Regional Council Regional clinical psychiatric hosp...
Kharkiv, Kharkivska, 61068, Ukraine
Municipal Non-profit Enterprise Odesa Regional Psychiatric Hospital No.2 of Odesa Regional Council
Kominternivskyy, Odesa Oblast, 67513, Ukraine
CI of KRC Regional psychiatric and narcological medical association
Hlevakha, 8631, Ukraine
Ivano-Frankivsk Oblast neuropsychiatric hospital No. 3
Ivano-Frankivsk, 76014, Ukraine
Academy of Medical Sciences of Ukraine - Institute of Neurology, Psychiatry and Narcology
Kharkiv, 61068, Ukraine
SI INPN Namsu
Kharkiv, 61068, Ukraine
Lviv Regional State Clinical Psychiatric Hospital, Lviv Danylo Galytsky National Medical University
Lviv, 79021, Ukraine
Odessa Regional Medical Centre of Mental Health
Odesa, 65006, Ukraine
Ukrainian Medical Stomatological Academy, Chair Of Psychiatry, Narcology And Medical Psychology B...
Poltava, 36006, Ukraine
Vinnitsa National Medical University
Vinnitsa, 21005, Ukraine
Related Publications (2)
Gill H, McIntyre RS, Christensen MC. Analysis of reward behavior in patients with MDD and partial response to SSRI therapy treated with vortioxetine versus desvenlafaxine: Experience with the Effort-Expenditure for Rewards Task (EEfRT) in the VIVRE study. J Affect Disord. 2025 Nov 1;388:119563. doi: 10.1016/j.jad.2025.119563. Epub 2025 May 31.
PMID: 40456468DERIVEDMcIntyre RS, Florea I, Pedersen MM, Christensen MC. Head-To-Head Comparison of Vortioxetine Versus Desvenlafaxine in Patients With Major Depressive Disorder With Partial Response to SSRI Therapy: Results of the VIVRE Study. J Clin Psychiatry. 2023 May 22;84(4):23m14780. doi: 10.4088/JCP.23m14780.
PMID: 37227402DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Email contact via H. Lundbeck A/S
LundbeckClinicalTrials@Lundbeck.com
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 23, 2020
First Posted
June 25, 2020
Study Start
June 18, 2020
Primary Completion
January 6, 2022
Study Completion
February 4, 2022
Last Updated
February 14, 2022
Record last verified: 2022-02
Data Sharing
- IPD Sharing
- Will share